The internet loves a good pharmaceutical plot twist. A drug designed for diabetes suddenly shows promise against cancer? That’s the kind of headline that gets people googling frantically and calling their oncologists. And based on new research from Cleveland Clinic, there’s actually something worth paying attention to here. But like most things in medicine, the reality is messier and more uncertain than the headlines suggest.
Researchers at Cleveland Clinic analyzed data from over 12,000 cancer patients with Stage 1 to 3 disease and found that those taking GLP-1 drugs like Ozempic and Wegovy showed reduced progression to more advanced stages compared to patients on DPP-4 inhibitors, an older class of diabetes medication. The findings will be presented at the 2026 American Society of Clinical Oncology meeting, though they haven’t yet been published in a peer-reviewed journal.
The numbers do look striking. Among breast cancer patients, 10% of those on GLP-1s progressed to stage IV cancer versus 20% of those on DPP-4s. For lung cancer, it was 10% versus 22%. Colorectal and liver cancer showed similar patterns of improvement.
So what’s actually happening here?
The Biology Behind the Buzz
Researchers observed that some cancer cells have high levels of GLP-1 receptors, and patients with these receptor-rich tumors showed a 33% lower risk of death when taking the medication. This suggests GLP-1 drugs might be doing more than just helping with weight loss and blood sugar control.
The proposed mechanism makes biological sense. According to the American Cancer Society, GLP-1s could slow cancer growth by affecting blood sugar and insulin levels, reducing inflammation, and boosting immune system function. These aren’t exactly radical ideas. Obesity itself is a known risk factor for multiple cancer types, and drugs that help patients lose weight and improve metabolic health could theoretically help cancer patients in multiple ways.
Dr. Marcin Chwistek from Fox Chase Cancer Center, speaking to HuffPost, noted that “their anti-inflammatory and immune-modulatory properties have long suggested broader effects.” He also emphasized what’s genuinely interesting about this data: the consistency across different tumor types. That’s not random noise. That’s a pattern worth investigating.
But Here’s Where It Gets Complicated
This is where we need to pump the brakes. The study is observational, not a randomized controlled trial. That means researchers watched what happened to patients already taking these drugs rather than randomly assigning some people to take GLP-1s and others to take something else. Observational studies can show correlations, but they can’t prove cause and effect.
Over half of the GLP-1 users were also taking active cancer treatments like chemotherapy or immunotherapy during the study period. Was it the GLP-1 that helped? The chemotherapy? Some combination? We don’t actually know.
Dr. Mark Orland, who led the Cleveland Clinic research, was refreshingly candid about the limitations. “We don’t have enough research,” he told HuffPost. “It’s too early to act on it.”
There’s another wrinkle that matters. The Cleveland Clinic researchers specifically chose DPP-4 inhibitors as their comparison group because, as Orland explained, “it was the least contentious of the group,” meaning it’s less likely to have its own cancer-fighting effects that could skew results. But when other researchers compared GLP-1s to a different diabetes drug class called SGLT2 inhibitors, the advantage disappeared. Dr. Jiang Bian from Indiana University’s School of Medicine found no difference between GLP-1s and SGLT2s, though he acknowledged his study had different limitations, including lacking access to patients’ body mass index data.
The simple truth: the choice of comparison drug matters hugely, and one study using one comparison doesn’t settle the question.
What This Means Right Now
Let’s be direct. GLP-1 drugs are not approved for cancer prevention or treatment. Cancer patients without Type 2 diabetes or obesity should not be asking their doctors for Ozempic or Wegovy hoping for anti-cancer benefits. That’s not what the evidence supports, and doing so could expose people to unnecessary risks and side effects.
For cancer patients who already take GLP-1s because they have diabetes or obesity, the situation is different but still uncertain. There’s no reason to stop taking the medication based on this data, but there’s also no reason to expect it to be a game-changer for their cancer outcomes.
Dr. Chwistek offered a careful but telling assessment: “While seeing real-world data show a 38% to 50% reduction in metastatic progression across lung, breast, colorectal, and liver cancers is an incredibly exciting catalyst for research, it does not instantly change standard oncological care.”
That’s the key phrase: catalyst for research. This is the beginning of an investigation, not its conclusion.
What Happens Next
Orland expects to be involved in future prospective randomized trials that could actually test whether GLP-1s directly impact cancer progression. Those studies will take years. They’ll cost millions. And they might show that the correlation in this observational data was misleading.
That’s not pessimism. That’s how science actually works. Most promising early findings don’t pan out at the level of evidence required to change clinical practice. Some do, and when they do, it’s usually because researchers followed up with rigorous testing.
For now, the honest answer to whether cancer patients should take GLP-1s to fight their disease is simple: we don’t know. What we do know is that obesity is a genuine risk factor for cancer, that GLP-1s can help with weight loss and metabolic health, and that a large observational study showed an intriguing pattern. Whether that pattern represents actual clinical benefit or statistical coincidence remains an open question worth pursuing carefully.
